PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)

Wu, Y-L.Wu, L.Bi, N.Cil, T.Ge, H.Zhu, Z.Wang, C-L.2026-04-042026-04-0420240923-75341569-8041https://doi.org/10.1016/j.annonc.2024.10.643https://hdl.handle.net/11616/109699European-Society-for-Medical-Oncology Asia Congress (ESMO) -- DEC 06-08, 2024 -- Singapore, SINGAPORE[No abstract available]eninfo:eu-repo/semantics/closedAccessPACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)Conference Object35S1624S162410.1016/j.annonc.2024.10.643WOS:001401985200400Q1